Ethic Inc. Sells 3,366 Shares of Illumina, Inc. (NASDAQ:ILMN)

Ethic Inc. lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 22.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,870 shares of the life sciences company's stock after selling 3,366 shares during the quarter. Ethic Inc.'s holdings in Illumina were worth $1,586,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Bank of Stockton grew its holdings in shares of Illumina by 3.8% during the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company's stock worth $289,000 after buying an additional 80 shares in the last quarter. Stephens Inc. AR grew its position in Illumina by 1.4% in the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company's stock valued at $885,000 after purchasing an additional 90 shares in the last quarter. Spire Wealth Management grew its position in Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock valued at $63,000 after purchasing an additional 97 shares in the last quarter. IFP Advisors Inc increased its stake in Illumina by 19.1% in the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock valued at $82,000 after buying an additional 99 shares during the last quarter. Finally, Freedom Investment Management Inc. lifted its position in Illumina by 3.7% during the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock worth $382,000 after buying an additional 101 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Price Performance

Shares of NASDAQ ILMN traded up $2.72 during mid-day trading on Friday, reaching $83.62. The company had a trading volume of 2,338,618 shares, compared to its average volume of 2,306,397. The firm has a market cap of $13.23 billion, a price-to-earnings ratio of -10.89, a PEG ratio of 1.60 and a beta of 1.35. The business's 50-day simple moving average is $78.50 and its 200 day simple moving average is $111.80. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The business's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.98 earnings per share. On average, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of Illumina stock in a transaction on Monday, May 12th. The shares were purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. This trade represents a 32.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.17% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ILMN shares. Stephens reaffirmed an "overweight" rating and issued a $156.00 target price on shares of Illumina in a research report on Tuesday, March 11th. Citigroup dropped their price objective on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Piper Sandler cut their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a report on Thursday. Canaccord Genuity Group cut their price objective on Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a research report on Monday. Finally, Royal Bank of Canada decreased their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $130.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.